AJP - Lung Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Lung Cell Mol Physiol 292: L1280-L1288, 2007. First published January 12, 2007; doi:10.1152/ajplung.00140.2006
1040-0605/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/5/L1280    most recent
00140.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sixt, S. U.
Right arrow Articles by Peters, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sixt, S. U.
Right arrow Articles by Peters, J.

Extracellular proteasome in the human alveolar space: a new housekeeping enzyme?

Stephan Urs Sixt,1 Martin Beiderlinden,1 Herbert Peter Jennissen,2 and Jürgen Peters1

1Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, and 2Institut für Physiologische Chemie II, Universität Duisburg-Essen, Essen, Germany

Submitted 13 April 2006 ; accepted in final form 1 January 2007


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
We hypothesized that 20S proteasome is present and functional in the extracellular alveolar space in humans. Proteasomal activity was measured in bronchoalveolar lavage (BAL) supernatant from eight humans using specific proteasomal fluorogenic substrates and I125-albumin with and without specific proteasome inhibitors. Furthermore, gelfiltration, Western blot technique, and mass spectrometry were applied for proteasome characterization. All proteasomal fluorogenic substrates were hydrolyzed by BAL supernatant, with hydrolysis inhibited by epoxomicin (P = 0.024) and other proteasome inhibitors as well. E64, a lysosomal inhibitor, did not inhibit enzyme activity. The majority of proteolytic activity was detected in BAL supernatant rather than in the cell pellet. No correlation was found between proteasomal hydrolysis in BAL supernatant and lactate dehydrogenase activity, the total cell count in the cell pellet, and the fraction of avital cells in the cell pellet, ruling out cell lysis as a major source of proteasomal activity. Gelfiltration revealed hydrolyzing activity in the supernatant at 660 kDa and proteasome core proteins after analysis by ESI-QqTOF mass spectrometry. Furthermore, Western blots using a polyclonal antibody against proteasomal {alpha}-/beta-subunits detected proteasomal proteins in the typical 20- to 30-kDa range in BAL supernatant. Incubation of BAL supernatant with I125-albumin showed a high mean cleavage rate (101.8 µg/ml x h lavage ± 46 SD) that was inhibited by epoxomicin (P = 0.013) and was ATP and ubiquitin independent. We identified for the first time extracellular, biologically active, ATP- and ubiquitin-independent 20S proteasome in the human alveolar space, with a high albumin cleavage rate. Possibly, the proteasome assists in maintenance of a low intra-alveolar oncotic pressure and/or alveolar protein degradation.

albumin; bronchoalveolar lavage; circulating proteasome; fluorogenic peptides; alveolar protein degradation; lung proteins

THE UBIQUITIN/PROTEASOME SYSTEM is a major pathway for selective intracellular non-lysosomal protein degradation in eukaryotic cells and plays an important role in numerous processes (3, 13, 53). The 20S proteasome is a multicatalytic proteinase complex with a cylinder-shaped structure arranged as four axially stacked heptameric rings composed of seven {alpha}-subunits (outer rings) and seven beta-subunits (inner rings) (36), respectively. Its catalytic sites are exclusively associated with the beta-subunits (40, 56) and are ATP and ubiquitin independent. The caspase-like activity of the beta1-subunit cleaves after acidic residues, the trypsin-like activity of the beta2-subunit cleaves after basic residues, and the chymotrypsin-like activity of the beta5-subunit cleaves after hydrophobic residues. Together, these three enzyme activities allow the proteasome to cleave many different substrates into diverse products. Within the cell, the 20S proteasome is associated with large ATP- and ubiquitin-dependent 19S regulatory cap-like complexes, together yielding a 26S complex. It is now well accepted that proteasomes are localized in both cell cytoplasm and nucleus (4, 50).

Whether proteasomes exist in the extracellular space under physiological conditions, however, has not been assessed. Vaithilingam et al. (61) described an extracellular proteasome-like structure with a molecular mass of 1,000 kDa released from cultured C6 astrocytoma cells that was able to degrade proteasomal fluorogenic substrates. This suggests that cells may secrete biologically active proteasome-like structures. However, investigations in vivo are missing, in particular, with regard to internal body surfaces.

Accordingly, we tested the hypothesis that biologically active proteasome is present physiologically in the extracellular alveolar space of humans and digests albumin, one of the predominant intra-alveolar proteins.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Eight Caucasian subjects (5 men, age 65 yr ± 4 SD) were included after approval of the local Ethics Committee and informed written consent. All subjects were free of lung, cardiac, infectious, and allergic disease and had no history of chemotherapy or radiation therapy.

Bronchoalveolar lavage (BAL) was performed during anesthesia preceding surgery [abdominal hernia repair (2), removal of cerebral tumor (4), thyroid resection (1), partial liver resection (1)] with a bronchoscope wedged in a right upper lobe segmental bronchus (2, 6). Recovered volume (81 ml ± 20, i.e., 51–63% of instilled volume) was filtered through gauze (34) to remove any visible particulate material and centrifuged (500 g, 10 min, 5°C). The supernatant was immediately frozen using liquid nitrogen and stored at –80°C. Cell counts were made in the pellet by counting an aliquot in a Neubauer chamber (34). Cell viability was determined by the Trypan blue dye exclusion technique (1). For differentiation of cells, smears were air-dried and stained according to May-Grunwald-Giemsa (6). The remaining cell pellet was frozen in liquid nitrogen and stored at –80°C. After cell lysis, the pellet was ultracentrifugated (30,000 g, 30 min), and its upper portion was used for further analysis (cell pellet lysate).

Hydrolyzing activities. Hydrolysis of proteasome-specific substrates was assayed with the fluorogenic substrates Suc-LLVY-AMC, BZ-VGR-AMC, and Suc-LLE-AMC (17).

Suc-LLVY-AMC (3-carboxy-propiony-Leu-Leu-Val-Tyr-7-amido-4-methylcumarin) is a fluorogenic substrate for the chymotrypsin-like activity of the proteasome (17).

BZ-VGR-AMC (benzoyl-Val-Gly-Arg-7-amido-4-methylcumarin) (5) is a substrate for the trypsin-like activity of the 20S proteasome. Suc-LLE-AMC (3-carboxy-propionyl-Leu-Leu-Glu-7-amido-4-methylcumarin) (48) is a fluorogenic substrate for the caspase-like (peptidylglutamyl-peptide hydrolyzing) activity of the proteasome.

The final concentration in the assay buffer system was: 100 µM fluorogenic substrate, 50 mM Tris·HCl, pH 8.0, 1 mM dithioerythritol (DTE), and 5 mM MgCl2. After incubation at 37°C for 60 min in a water bath, the reaction was inhibited irreversibly at specified time intervals by ethanol (20 min, 0°C). Release of 7-amido-4-methylcoumarin (AMC) was detected by spectrophotometry (RF-10A Xl, Shimadzu, Duisburg, Germany) with an excitation ({lambda}ex) of 380 nm and an emission ({lambda}em) of 460 nm. The final protein concentration for the cell pellet assay was 2 mg/ml. Since protein concentration in the BAL supernatant was so low that a final protein concentration of 2 mg/ml could not be achieved, 104 µl of BAL supernatant were taken into each assay for all subjects. All samples from all subjects were measured separately in duplicate. Duplicate measurements were averaged for each single subject, and these eight values were used for statistical analysis.

Inhibition of proteasome activity. To assess potential inhibition of hydrolysis, 10 µM epoxomicin (43) (Calbiochem, San Diego, CA) was added to the incubation mixture in separate assays to samples from all eight subjects. For determination of EC50 for epoxomicin inhibition of hydrolyzing activity in BAL supernatant, increasing concentrations of epoxomicin from 0.0001 to 15 µM were used. Epoxomicin is a novel, highly specific epoxy-ketone tetrapeptide proteasome inhibitor. It is cell permeable, potent, selective, and irreversible (43). It is the most potent and selective proteasome inhibitor currently available. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome. It inhibits all three enzyme activities of the proteasome (43).

In addition, we also studied (n = 8) the effects of other specific inhibitors (Calbiochem) of proteasomal activity such as proteasome inhibitor II (49) (concentrations of 0.001–70 µM), MG-132 (39) (concentrations of 0.01–70 µM), and thyropeptin A (45) (concentrations of 0.01–100 µM). Proteasome inhibitor II (48) is a substrate-related inhibitor (Z-LLF-CHO) and inhibits the chymotryptic-like and tryptic-like activity. The inhibitor is cell permeable. Proteasome inhibitor IV (63) also mediates substrate-related inhibition and is a weak inhibitor of the chymotryptic-like activity. It also inhibits the caspase-like activity and weakly inhibits the tryptic-like activity. MG-132 (39) is a potent and selective reversible proteasome inhibitor mediating substrate-related inhibition (Z-Leu-Leu-Leu-CHO). It inhibits the chymotryptic-like activity and the tryptic-like activity. The caspase-like activity is not inhibited by MG-132. It also inhibits cathepsins and calpains (cysteine proteases). Thyropeptin A (45) is cell permeable and mediates competitive and reversible inhibition. It inhibits the chymotryptic-like and the tryptic-like activity of the proteasome.

To exclude effects on enzyme activity by lysosomal enzymes, we also studied the effect of the lysosomal inhibitor E64 (500 µM). E64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane] (28) is an potent, irreversible, cell-permeable, and highly selective cysteine protease inhibitor, and E64 does not inhibit serine proteases (except trypsin) like the cysteine protease inhibitors, leupeptin, and antipain. The trans-epoxysuccinyl group (active moiety) of E64 irreversibly binds to an active thiol group of many cysteine proteases such as papain, actinidase, and cathepsins B, H, and L (58) to form a thioether linkage. The mechanism of inhibition of some cysteine proteases including cathepsins B and L, and of trypsin, have been reported (58).

We used fluorogenic substrate cleavage related to total protein [picokatal (pkat)/mg] to describe the specific enzyme activity of extracellular proteasome. We also calculated the volume-related enzyme activity of the BAL (pkat/ml) to derive total enzyme activity of the BAL recovery expressed as pkat (pkatBAL = pkat/ml x ml BAL recovery). Thus volume-related activity is expressed as U/ml (= katal/ml), and specific activity is expressed as U/mg (= katal/mg = mol/mol x s).

125I-labeling of BSA. Twenty-five micrograms of BSA were iodinated (62), mixed with 2.5 mg BSA, acetylated (67), and dialyzed against 20 mM Tris·HCl, pH 7.8. It was then precipitated by 5% wt/vol TCA. The pellet was resuspended in 300 µl of 1.0 M NaOH, diluted to a total volume of 6 ml in millipore water, heated to 60°C for 15 min, and stored at –80°C (125I-BSA stock solution). Methylated 125I-BSA was prepared according to Hershko et al. (29).

Proteolysis of 125I-BSA. ATP-dependent proteolysis was measured as previously described (14, 67), and the assay was modified (25) for the measurements in BAL supernatant from eight individuals in separate assays. Proteolysis was measured in the presence and absence of 10 mM EDTA and 10 µM epoxomicin, respectively. Incubation mixture 1 (total vol 0.1 ml) for ATP/Mg2+-dependent activity (+ATP) had the following final concentrations: 10 µg/ml pure 125I-BSA and 50 µl sample of BAL supernatant, 50 mM Tris·HCl, pH 8.0, 1 mM DTE, 5 mM ATP, and 5 mM Mg2+. Mixtures with buffer instead of sample were incubated as controls. For measurement of ATP/Mg2+-independent proteolytic activity (mixture 2), 10 mM EDTA (–ATP) was added to mixture 1. For the incubation mixture +ATP/+ubiquitin (final concentration: 0.1 mg/ml ubiquitin), ubiquitin was added to mixture 1. For the incubation mixture –ATP/+epoxomicin (proteasome-independent activity), 10 µM (final concentration) epoxomicin (mixture 3) was added to mixture 2. After incubation at 37°C for 120 min, 0.125 ml 10% wt/vol TCA and 0.025 ml unlabeled BSA (30 mg/ml) were added to the mixtures and placed on ice (0°C) for 20 min. After centrifugation (Eppendorf 5415; Eppendorf, Hamburg, Germany) for 2 min at 14,000 g, the TCA-soluble radioactivity in the supernatant was measured in a gamma counter (Gammaszint BF 5300; Berthold, Cologne, Germany). Activity was expressed as U/ml as follows

Formula

Formula

SDS-PAGE. SDS-PAGE was performed with Mini-Protean 3 Electrophoresis (Bio-Rad) with 15% gels according to Laemmli (38). Fifty micrograms of protein per lane were applied. The molecular weight standard was SeeBlue Pre-Stained Standard obtained from Invitrogen.

Western blots. To detect the presence of proteasomal proteins, samples (50 µg/lane) were subjected to SDS-PAGE and transferred to PVDF (Bio-Rad) under semidry conditions with the use of a Trans-Blot Semi-Dry Electrophoretic Transfer Cell (Bio-Rad). After blocking the PVDF membranes by incubation with TBS-Tween buffer (5% Tween 20, 150 mM NaCl, 20 mM Tris·HCl, pH 7.6) and StartingBlock blocking buffer (Pierce) for 24 h at 4°C, the membranes were incubated (dilution 1:1,000, 2 h, room temperature) with rabbit polyclonal antibody to 20S proteasome {alpha}-/beta-subunits (Biomol International; PW 8155). After being washed with TBS-Tween buffer (5% Tween 20, 150 mM NaCl, 20 mM Tris·HCl, pH 7.6), the membranes were incubated (1:10,000, 1 h, room temperature) with peroxidase-conjugated, affinity-isolated goat anti-rabbit IgG (Sigma Aldrich). After washing, the chemiluminescence method was employed to detect the peroxidase activity using an ECL kit (SuperSignal West Pico Chemiluminescence Substrate, Pierce).

Gelfiltration. Gelfiltrations (6 separate runs from 6 individuals) were performed on a Superose 6PG column (internal diameter: 1 cm, length: 40-cm packed gel, Amersham Bioscience) in 20 mM Tris·HCl, 10% glycerol, 100 mM NaCl, pH 7.5 (54), at 5°C. The column had been previously calibrated using proteins of known molecular mass: thyreoglobulin (668 kDa), ferritin (446 kDa), catalase (232 kDa), aldolase (158 kDa), IgG (160 kDa), BSA (67 kDa), ovalbumin (45 kDa), trypsin inhibitor (20.1 kDa), and cytochrome c (12.4 kDa). Molecular masses of the enzyme fractions were calculated by nonlinear regression based on the respective calibration function.

Lactate dehydrogenase activity. As a marker of possible cell damage, BAL supernatants were analyzed for total (LDH1-LDH5) lactate dehydrogenase (LDH) activity by a kinetic UV test (Diaglobal) using an optimized standard method (IFCC).

Albumin and total protein concentration. Albumin concentration in BAL supernatant in eight subjects was measured using an ELISA (Dade Behring, Marburg, Germany). Total protein in the BAL supernatant was determined after TCA precipitation (5%), washing, and resolubilization according to Lowry et al. (41) using an AutoAnalyzer (Technicon) employing BSA as a standard. Since albumin is the predominant protein (18) in the BAL, measured albumin concentrations were subtracted from the total protein. Hence, all data on hydrolyzing activity were referenced to albumin-depleted total protein.

ESI-QqTOF-mass spectrometry. To analyze proteins in the peak Suc-LLVY-AMC eluate activity of the BAL supernatant (fractions 22–26) (as described above) and the cell pellet lysate (fractions 21–24) gel spots in a molecular range (above 20 kDa) likely to contain proteasomal proteins, if present, were excised from the SDS-PAGE of one individual and subjected to electrospray ionization mass spectrometry measurements (44). This technique provides a plot of detector signal intensity (abundance of ions) vs. the mass-to-charge ratio (of ions produced in the instrument; m/z). Such a plot is called a mass spectrum and is considered a "fingerprint" of a molecule, which may be identified by a positive comparison with a mass spectrum obtained from a known sample. Specifically, a sample is introduced into the gas phase and exposed to an ion source. Here, the substance (MH) is bombarded with electrons. Electrons interact in such a way as to produce positive ions of the substance, according to the equation MH + e– -> MH+ 2e–. The MH+ ion has essentially the same mass as the original substance, so it is called a molecular ion. Enough energy is imparted to the substance during ionization that most molecules fragment, producing fragment ions with a smaller mass-to-charge ratio. The mass of the fragment ions and the abundance of ions at each mass varies widely among molecules and thus are unique for a particular molecule. Some molecules break apart so readily that no molecular ion remains. The fingerprint of the cracked molecules allows identification of (all) proteins present in the gel as long as they are listed in the database.

Chemicals. All chemicals were of highest available or analytical grade. Water was deionized, distilled, and passed through a Milli-Q-System (Millipore) before use.

Statistical analysis. Data are described as medians (box and whisker plots) or means ± SD. Values of variables were compared using a Wilcoxon or paired sample t-test, as appropriate, using SPSS 11.0 (Chicago, IL). Differences were regarded as statistically significant with an {alpha}-error (P) of less than 0.05.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
All three proteasomal-specific fluorogenic substrates (16, 59) were hydrolyzed in the BAL supernatant and in the cell pellet lysate (Fig. 1, A and B). Furthermore, all three hydrolytic activities in BAL supernatant were significantly inhibited by 10 µM epoxomicin (43) (Fig. 1, A and D), the most potent and selective inhibitor currently available, with an EC50 of 210 nM, 1.1 µM, and 3.4 µM for hydrolysis of Suc-LLVY-AMC (Fig. 1D), BZ-VGR-AMC, and Suc-LLE-AMC, respectively. The EC50 for the hydrolysis of Suc-LLVY-AMC, BZ-VGR-AMC, and Suc-LLE-AMC was 200 nM, 40.7 µM, and 2 µM for proteasome inhibitor II, 2.1 µM, 10.65 µM, and 3.12 µM for thyropeptin A, and 0.31 µM, 0, and 0 for MG-132, respectively. Incubation with the lysosomal inhibitor E64 (Fig. 1E) had no effect on the hydrolysis of fluorogenic substrates.


Figure 1
View larger version (19K):
[in this window]
[in a new window]

  		Fig. 1. A and B: hydrolysis of proteasome-specific fluorogenic substrates in bronchoalveolar lavage (BAL) supernatant and cell pellet lysate from 8 humans undergoing BAL. All measurements were performed in duplicate and averaged for each subject. Data from 8 individual values are shown as box and whisker plots with the median, the upper quartile, the lower quartile, and the 2 extreme values of the data set displayed. Suc-LLVY-AMC, BZ-VGR-AMC and Suc-LLE-AMC-hydrolyzing activity without (open bars) and with 10 µM epoxomicin (hatched columns) in BAL supernatant (A) and BAL cell pellet lysate (B). Hydrolyzing activity was present for all substrates in BAL supernatant and was significantly inhibited by epoxomicin. C: fraction of total hydrolyzing activity in BAL supernatant and cell pellet. Data from 8 subjects. The main fraction of total hydrolyzing activity is present in the BAL supernatant. D: EC50 for epoxomicin inhibition of hydrolyzing activity in BAL supernatant was 210 nM for Suc-LLVY-AMC. Data from 8 subjects (means ± SD). E: hydrolysis of proteasome-specific fluorogenic substrates in BAL supernatant from 6 subjects without (open bars) and with 500 µM E64 (hatched columns). pkat, Picokatal.

 
Of note, the majority (94–62%) of the total proteolytic activity was found in BAL supernatant (Fig. 1C) rather than in the cell pellet lysate. Cell lysis resulting from the centrifugation step itself can be excluded (Fig. 2D) as a major source of proteasome activity in BAL supernatant since only 0.1% of the hydrolyzing activity resulted from cell lysis, as shown by exemplary centrifugation of blood samples. Furthermore, all alveolar cells observed by direct microscopy and after staining with May-Grunwald-Giemsa and trypan blue had intact cell membranes. Also, there was no correlation between the enzyme activities in the BAL supernatant measured with proteasome-specific substrates and LDH activity (Fig. 2A), a marker of cell lysis, the cell count in the cell pellet (Fig. 2B), and the fraction of cells in the cell pellet taking up trypan blue (Fig. 2C).


Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		Fig. 2. Correlation of Suc-LLVY-AMC hydrolyzing activity in BAL supernatant with markers of cell damage. There are no correlations between Suc-LLVY-AMC hydrolyzing activity in the BAL supernatant and lactate dehydrogenase (LDH) activity (8 subjects) in BAL supernatant (A), the cell count (8 subjects) in BAL cell pellet (B), and the fraction of cells in the cell pellet taking up trypan blue (C; 5 subjects). Centrifugation of blood (8 subjects) does not increase Suc-LLVY-AMC enzyme activity in the supernatant (D). Box and whisker plots are shown.

 
Determination by gelfiltration of molecular mass in the BAL supernatant yielded a molecular weight of 660 kDa, but one of 1,000 kDa in the cell pellet lysate (Fig. 3), consistent with the 20S proteasome and 26S proteasome, respectively. Similar results were obtained for BZ-VGR-AMC and Suc-LLE-AMC. The purification table (Fig. 3) illustrates that Suc-LLVY-AMC enzyme activity of the eluate peaks (fractions 22–26) of the BAL supernatant was purified 2.49-fold by gelfiltration and represents 11.4% of protein. This indicates a yield of 249%, possibly due to the elimination of an inhibitor.


Figure 3
View larger version (33K):
[in this window]
[in a new window]

  		Fig. 3. Molecular mass determination of SUC-LLVY-AMC hydrolyzing activity peak in BAL supernatant ({blacktriangleup}) and cell pellet lysate ({triangleup}) by gelfiltration. Typical example of 6 gelfiltration experiments from 6 individuals. A purification table is depicted below. Fractions containing Suc-LLVY-AMC hydrolyzing activity were purified on a Superose 6PG column. Molecular masses of the fractions were calculated by nonlinear regression based on the respective calibration function ({blacklozenge}). 0.8 mg protein of the pellet and 0.1 mg protein of BAL supernatant were applied to the gelfiltration column. The protein responsible for hydrolyzing activity in the supernatant had a molecular mass of 660 kDa, consistent with the 20S proteasome, and that of the cell pellet lysate had a molecular weight (MW) of 1,000 kDa, consistent with the 26S proteasome, respectively.

 
Western blots of BAL supernatant using the primary polyclonal antibody against {alpha}-/beta-proteasomal subunits showed typical proteasomal protein bands in the 20- to 30-kDa range in all eight subjects (Fig. 4, A and B). Of note, the Western blots showed a different arrangement of proteasomal protein bands in BAL supernatant and cell pellet.


Figure 4
View larger version (58K):
[in this window]
[in a new window]

  		Fig. 4. Western blots with a polyclonal antibody against the {alpha}- and beta-subunits of the 20S proteasomal core of BAL supernatant and BAL cell pellet data from 8 subjects. Fifty micrograms of protein were applied to each lane. Lanes are identified as follows. A: lane 1, 1 µg 20S proteasome standard; lane 2, cell pellet subject 1; lane 3, BAL supernatant subject 1; lane 4, cell pellet subject 2; lane 5, BAL supernatant subject 2; lane 6, cell pellet subject 3; lane 7, BAL supernatant subject 3; lane 8, cell pellet subject 4; lane 9, BAL supernatant subject 4. B: lane 1, 1 µg 20S proteasome standard; lane 2, cell pellet subject 5; lane 3, BAL supernatant subject 5; lane 4, cell pellet subject 6; lane 5, BAL supernatant subject 6; lane 6, cell pellet subject 7; lane 7, BAL supernatant subject 7; lane 8, cell pellet subject 8; lane 9, BAL supernatant subject 8.

 
ESI-QqTOF showed the presence of proteasome subunit {alpha}3 (PSMA3), proteasome subunit {alpha}4 (PSAM4), and proteasome subunit {alpha}6 (PSMA6) (Table 1). Of note, peptides derived from 19S proteasomal caps (PSD3, PSD4, PSD11, PSD13) were exclusively found in the cell pellet lysate but not in the BAL supernatant. In addition, we found in BAL supernatant heat shock protein 90 (HSP 90), HSP70, and chaperonin containing TCP-1. Two of the protein spots could not be specified because signals could not be related to known proteins in the data base.


View this table:
[in this window]
[in a new window]

  		Table 1. Analysis by ESI-QqTOF-mass spectrometry of proteins contained in peak Suc-LLVY-AMC eluate activity (gelfiltration fractions 22–26) of BAL supernatant from one individual

 
To test for proteasomal albumin degradation and for its ATP and ubiquitin dependency, BAL supernatants were incubated with 125I-albumin in subsequent experiments. As shown in Fig. 5, albumin degradation by BAL supernatant was present, was not ubiquitin or ATP dependent, and was inhibited (P = 0.013) by epoxomicin. Albumin degradation in BAL supernatant averaged 101.8 ± 46 µg/ml lavage/hour. The total protein concentration in the BAL supernatant ranged from 100 to 300 µg/ml, with an average albumin concentration of 41.5 ± 20 µg/ml.


Figure 5
View larger version (11K):
[in this window]
[in a new window]

  		Fig. 5. Albumin proteolysis in BAL supernatant. Data from 8 individuals are shown. Box and whisker plots are used. Albumin proteolysis was present in BAL supernatant and could be significantly inhibited by 10 µM epoxomicin. Albumin degradation was ATP and ubiquitin independent.

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
These findings indicate that 20S proteasome is present physiologically in the extracellular alveolar space in humans, as shown by hydrolysis of specific proteasomal fluorogenic substrates in BAL supernatant, its inhibition by the highly specific proteasome inhibitor epoxomicin as well as by other specific proteasome inhibitors, absence of inhibition by lysosomal inhibitor E64, the presence of proteasomal proteins as revealed by Western blots and mass spectrometry, and a molecular mass of 660 kDa, consistent with 20S proteasome (66). Furthermore, 125I-albumin was degraded in an ATP- and ubiquitin-independent manner, and this was also inhibited by epoxomicin, indicating that the extracellular proteasome found in the alveolus is also biologically active and can degrade albumin.

This questions several fundamental aspects of currently favored models of physiological proteasome localization and function. First, our data demonstrate for the first time that 20S proteasome is not only present extracellularly in the lung but also that it is enzymatically intact and active in the human alveolar space. Second, the 20S proteasome found degrades albumin, physiologically present in the alveolar space, with a high cleavage rate. Although the proteasome is known to degrade albumin, a feature used to describe tissue-related proteasomal activity (32), the idea that albumin is a physiological substrate of the proteasome in the extracellular alveolar space has not been addressed.

A 26S proteasome-mediated degradation of albumin in the BAL supernatant can be excluded because of the strict ATP and ubiquitin independency found. In fact, only the 19S caps of the 26S proteasome require ATP and ubiquitin for protein degradation (13, 32). Remarkably, the albumin cleavage rate in BAL supernatant found in vitro by the extracellular proteasome is greater than albumin degradation formerly assumed to occur in the alveolar space (7, 22–24, 26, 42). Possibly, differences in radiolabeling techniques of albumin account for this difference. We used, for stable proteolysis, a chloramin T technique (62) with subsequent acetylation (67) and methylation of albumin (29) to allow more reliable and more stable measurements of proteasomal albumin degradation (29). In any case, 125I-albumin degradation by other catalytic enzymes of the extracellular alveolar space can be excluded because epoxomicin, a highly specific proteasome inhibitor, significantly inhibited albumin degradation in BAL supernatant.

Extracellular proteasome in the alveolar space by degrading albumin might be involved in the maintenance of a low intra-alveolar oncotic pressure. In fact, due to the high proteasome-dependent albumin cleavage rate observed, alveolar albumin load could increase 2.45-fold before degradation capacity would be exhausted. Considering that a BAL sample represents only ~1.5–3% of the alveolar space (27) and that recovery of BAL fluid from the lung averaged 81 ml, albumin degradation capacity measured in BAL supernatant is substantial quantitatively. Of note, BAL of a lung segment is believed to represent ~1 ml of epithelial lining fluid (64). Thus proteasome activity in the alveolar epithelial lining fluid in vivo might be many times greater than that measured in the BAL supernatant in our subjects.

Since alveolar albumin concentration can increase in lung diseases (47), it would be of interest to assess alveolar proteasomal albumin degradation in lung disease. Inflammatory acute and chronic lung disease where alveolar protein concentrations can increase dramatically would be of particular interest. Furthermore, since the alveolar space is an external surface, second only to the gastrointestinal tract in dealing with environmental antigens, it is conceivable that extracellular proteasome in the lung, besides albumin, degrades other alveolar proteins as well. In this respect, HSPs (11) and chaperonins (51, 52) also found in the alveolar space may assist the 20S proteasome in unfolding and digesting target proteins in the absence of 19S caps and the intracellular ubiquitin system.

A biologically active proteasome has not been demonstrated previously in the extracellular space of human lungs. Cell lysis as a major source of extracellular proteasome can be ruled out since neither BAL nor centrifugation resulted in cell damage or significant cell lysis. Furthermore, total extracellular proteasomal activity in the BAL supernatant was much higher than total activity in BAL cell pellet lysate itself. If proteasomal activity in BAL supernatant had been the result of cell lysis, total activity would not be higher in the supernatant than in the cell pellet. Finally, if the proteasome in BAL supernatant would have resulted only from cell lysis, the pattern of enzymatic activity in BAL supernatant and cell pellet should have been identical. In contrast, we observed that Suc-LLVY-AMC was the major activity in BAL supernatant, whereas BZ-VGR-AMC was the major activity in the cell pellet. Furthermore, Western blots showed that the pattern of proteasomal proteins, as labeled by the antibody against core proteins, was different in BAL supernatant and cell pellet lysate. In addition, we did not find contamination of BAL fluid by airway epithelial cells, but mainly alveolar macrophages and white cells, ruling out major contamination of BAL from airways. Together, these findings are inconsistent with extracellular proteasomal activity simply resulting from cell lysis. Nevertheless, even if alveolar proteasomal activity in the BAL supernatant would have resulted in part from alveolar lining cell turnover and lysis, our data would indicate that this is associated with substantial albumin proteolysis.

We used for BAL in humans the gold standard technique clinically available for alveolar sampling. We did not use the technique described by Ware et al. (65), inserting blindly a catheter into the airways via an endotracheal tube, since this method yields only a small recovery in healthy subjects without pulmonary edema. Thus our sampling technique employed yields the most reliable alveolar sample possible in humans.

Traditionally, the proteasomal system is considered to have intracellular functions, and the extracellular role of proteasomes has not yet been explored in the human lung. However, there is increasing evidence that proteasomes can exert physiological roles in the extracellular space, too. Of interest, extracellular proteasomal activity has been suggested for ascidian fertilization and sperm penetration of the viteline coat (55). In addition, proteasome and proteasome subunits have been detected in sera of patients with autoimmune disease (21) and were described as "circulating proteasome" (19-21, 60). Furthermore, particles of proteasomal structure have been detected on the cell surface of lymphocytes (12), and Vaithilingam et al. (61) described an extracellular proteasome-like structure released from cultured C6 astrocytoma cells with a molecular mass of 1,000 kDa, able to degrade collagen IV, {alpha}-casein, beta-insulin, and synthetic proteasomal peptide substrates. In support of our findings, this suggests that human cells may secrete biologically active proteasomal structures.

Proteins larger than the 20S proteasome, such as {alpha}2-macroglobuline (820 kDa) and immunoglobulin M (900 kDa), are found in the BAL, too (10, 18, 33). The dimension of the 20S proteasome is 15 x 12 nm (37). Williams (68) found vesicles in the alveolar epithelium with radii as large as 130 nm. Thus transport mechanisms of adequate size are present for expulsion of proteasome from the alveolar epithelium. Alternatively, alveolar macrophages could release proteasome core proteins, but this has not been assessed.

Furthermore, the potential cellular source of the extracellular proteasome is unknown. The fact that the majority of activity was found in BAL supernatant rather than BAL cell pellet does not imply that 20S proteasome is brought into the extracellular space exclusively by resident cells of the alveolar space. In fact, data from Zoeger et al. (69) show in the blood proteasomal molecules that do not derive from platelets, red blood cells, or other blood-borne cells, suggesting that endothelial cells or other organs may secrete proteasome. Thus, extracellular alveolar proteasome could also derive from the blood stream.

In our study, we exclusively found 20S proteasome in the extracellular alveolar space, but not 26S proteasome, as indicated by gelfiltration experiments and molecular weight determination, and the ATP/ubiquitin independence. The 20S proteasome is a smaller protein complex than the 26S proteasome. Possibly, it is easier for cells to transfer into the extracellular space a 660-kDa protein than a 1,000-kDa protein. Furthermore, intracellular protein degradation via the 26S proteasome system requires a very complex enzyme cascade (E1-E4) including ubiquitylation and deubiquitylation and the presence of 19S proteasomal caps. Teleologically, it is not plausible how the alveolar space would set up and maintain such a complex and regulated enzyme system outside the cell. Instead, HSPs (11) and chaperonins (51, 52) in the alveolar space may assist the 20S proteasome in unfolding and digesting target proteins in the absence of the (intracellular) 19S proteasome caps and the ubiquitin system. Finally, our data showed protein degradation via the 20S proteasome independent of ATP and ubiquitin, without the presence of 19S caps required. This is consistent with the general principle that extracellular enzymes have to function without ATP because of its absence extracellularly.

Our findings also show that there is more extracellular alveolar machinery for protein degradation than previously known. Because of its ubiquitin independence, the extracellular proteasome described in this study may adopt a clearance function for proteins independent of the complex regulation described for the intracellular proteasome.

Furthermore, since proteasomal degradation is known to result in oligopeptides (13), the extracellular alveolar proteasome might be involved in extracellular antigen processing before antigens are presented to immune cells. However, it cannot be excluded that the alveolar proteasome besides protein degradation has other functions unrelated to protein digestion. In this context, the concept of moonlighting proteins, i.e., proteins that have completely different functions depending on their presence in different intracellular and extracellular compartments, is an interesting approach (8, 9, 15, 30, 31, 35, 46, 57).

In summary, biologically active 20S proteasome is physiologically present and functional in the extracellular human alveolar space and can degrade albumin. Its multicatalytical character and substantial albumin cleavage rate suggest that it has a biological role in alveolar protein degradation.


   ACKNOWLEDGMENTS
 
We appreciate the excellent technical assistance of U. Brecklinghaus and B. Hermann. We thank S. Metzger and M. Laub for MS/MS analysis and radiolabeling. Furthermore, we thank J. Hakenbeck, D. Spyrka, R. Alami, and B. Saul.


   FOOTNOTES
 

Address for reprint requests and other correspondence: J. Peters, Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany (e-mail: juergen.peters{at}uni-essen.de)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 141: S169–S202, 1990.[Web of Science][Medline]
  2. The European Society of Pneumology Task Group. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 2: 561–585, 1989.[Web of Science][Medline]
  3. Ahn JY, Tanahashi N, Akiyama K, Hisamatsu H, Noda C, Tanaka K, Chung CH, Shibmara N, Willy PJ, Mott JD, Slaughter CA, DeMartino GN. Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome. FEBS Lett 366: 37–42, 1995.[CrossRef][Web of Science][Medline]
  4. Ahn K, Erlander M, Leturcq D, Peterson PA, Fruh K, Yang Y. In vivo characterization of the proteasome regulator PA28. J Biol Chem 271: 18237–18242, 1996.[Abstract/Free Full Text]
  5. Andersson M, Sjostrand J, Karlsson JO. Differential inhibition of three peptidase activities of the proteasome in human lens epithelium by heat and oxidation. Exp Eye Res 69: 129–138, 1999.[CrossRef][Web of Science][Medline]
  6. Hasslam PL, Baughmann RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 14: 245–248, 1999.[Web of Science][Medline]
  7. Berthiaume Y, Albertine KH, Grady M, Fick G, Matthay MA. Protein clearance from the air spaces and lungs of unanesthetized sheep over 144 h. J Appl Physiol 67: 1887–1897, 1989.[Abstract/Free Full Text]
  8. Bielli P, Calabrese L. Structure to function relationships in ceruloplasmin: a ‘moonlighting’ protein. Cell Mol Life Sci 59: 1413–1427, 2002.[CrossRef][Web of Science][Medline]
  9. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82: 53–73, 2003.[CrossRef][Web of Science][Medline]
  10. Braley JF, Dawson CA, Moore VL. Immunologic block against antigen absorption from isolated perfused rabbit lungs. J Immunol 121: 926–929, 1978.[Abstract/Free Full Text]
  11. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 92: 351–366, 1998.[CrossRef][Web of Science][Medline]
  12. Bureau JP, Henry L, Baz A, Scherrer K, Chateau MT. Prosomes (proteasomes) changes during differentiation are related to the type of inducer. Mol Biol Rep 24: 57–62, 1997.[CrossRef][Web of Science][Medline]
  13. Ciechanover A, Iwai K. The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 56: 193–201, 2004.[Web of Science][Medline]
  14. Ciehanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 81: 1100–1105, 1978.[CrossRef][Web of Science][Medline]
  15. Copley SD. Enzymes with extra talents: moonlighting functions and catalytic promiscuity. Curr Opin Chem Biol 7: 265–272, 2003.[CrossRef][Web of Science][Medline]
  16. Dahlmann B, Ruppert T, Kloetzel PM, Kuehn L. Subtypes of 20S proteasomes from skeletal muscle. Biochimie 83: 295–299, 2001.[Medline]
  17. Dang LC, Melandri FD, Stein RL. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 37: 1868–1879, 1998.[CrossRef][Medline]
  18. Delacroix DL, Marchandise FX, Francis C, Sibille Y. Alpha-2-macroglobulin, monomeric and polymeric immunoglobulin A, and immunoglobulin M in bronchoalveolar lavage. Am Rev Respir Dis 132: 829–835, 1985.[Web of Science][Medline]
  19. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, Burmester GR, Kloetzel PM, Feist E. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 29: 2045–2052, 2002.[Abstract/Free Full Text]
  20. Feist E, Dorner T, Kuckelkorn U, Scheffler S, Burmester G, Kloetzel P. Diagnostic importance of anti-proteasome antibodies. Int Arch Allergy Immunol 123: 92–97, 2000.[CrossRef][Web of Science][Medline]
  21. Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzel PM. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 184: 1313–1318, 1996.[Abstract/Free Full Text]
  22. Folkesson HG, Matthay MA, Westrom BR, Kim KJ, Karlsson BW, Hastings RH. Alveolar epithelial clearance of protein. J Appl Physiol 80: 1431–1445, 1996.[Abstract/Free Full Text]
  23. Folkesson HG, Westrom BR, Karlsson BW. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. Acta Physiol Scand 139: 347–354, 1990.[Web of Science][Medline]
  24. Folkesson HG, Westrom BR, Pierzynowski SG, Svendsen J, Karlsson BW. Lung to blood passage of albumin and a nonapeptide after intratracheal instillation in the young developing pig. Acta Physiol Scand 147: 173–178, 1993.[Web of Science][Medline]
  25. Gehrke PP, Jennissen HP. ATP-dependent proteolysis and the role of ubiquitin in rabbit cardiac muscle. Biol Chem Hoppe Seyler 368: 691–708, 1987.[Web of Science][Medline]
  26. Goodale RL, Goetzman B, Visscher MB. Hypoxia and iodoacetic acid and alveolocapillary barrier permeability to albumin. Am J Physiol 219: 1226–1230, 1970.[Free Full Text]
  27. Harbeck RJ. Immunophenotyping of bronchoalveolar lavage lymphocytes. Clin Diagn Lab Immunol 5: 271–277, 1998.[Medline]
  28. Hashida S, Kominami E, Katunuma N. Inhibitions of cathepsin B and cathepsin L by E-64 in vivo. II. Incorporation of [3H]E-64 into rat liver lysosomes in vivo. J Biochem 91: 1373–1380, 1982.[Abstract/Free Full Text]
  29. Hershko A, Heller H, Eytan E, Kaklij G, Rose IA. Role of the alpha-amino group of protein in ubiquitin-mediated protein breakdown. Proc Natl Acad Sci USA 81: 7021–7025, 1984.[Abstract/Free Full Text]
  30. Jeffery CJ. Moonlighting proteins: old proteins learning new tricks. Trends Genet 19: 415–417, 2003.[CrossRef][Web of Science][Medline]
  31. Jeffery CJ. Multifunctional proteins: examples of gene sharing. Ann Med 35: 28–35, 2003.[CrossRef][Web of Science][Medline]
  32. Jennissen HP. Ubiquitin and the enigma of intracellular protein degradation. Eur J Biochem 231: 1–30, 1995.[Web of Science][Medline]
  33. Kim KJ, Malik AB. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol 284: L247–L259, 2003.[Abstract/Free Full Text]
  34. King TE. The handling and analysis of bronchoalveolar lavage specimens. In: Bronchoalveolar lavage, edited by Baughman RP. St. Louis, MO: Mosby Year Book, 1992, p. 3–29.
  35. Klopfenstein DR, Vale RD, Rogers SL. Motor protein receptors: moonlighting on other jobs. Cell 103: 537–540, 2000.[CrossRef][Web of Science][Medline]
  36. Kopp F, Hendil KB, Dahlmann B, Kristensen P, Sobek A, Uerkvitz W. Subunit arrangement in the human 20S proteasome. Proc Natl Acad Sci USA 94: 2939–2944, 1997.[Abstract/Free Full Text]
  37. Kopp F, Steiner R, Dahlmann B, Kuehn L, Reinauer H. Size and shape of the multicatalytic proteinase from rat skeletal muscle. Biochim Biophys Acta 872: 253–260, 1986.[CrossRef][Medline]
  38. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685, 1970.[CrossRef][Medline]
  39. Lee DH, Goldberg AL. Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem 271: 27280–27284, 1996.[Abstract/Free Full Text]
  40. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 34 A resolution. Science 268: 533–539, 1995.[Abstract/Free Full Text]
  41. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275, 1951.[Free Full Text]
  42. Matthay MA, Berthiaume Y, Staub NC. Long-term clearance of liquid and protein from the lungs of unanesthetized sheep. J Appl Physiol 59: 928–934, 1985.[Abstract/Free Full Text]
  43. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96: 10403–10408, 1999.[Abstract/Free Full Text]
  44. Meyer S, Metzger JO. Use of electrospray ionization mass spectrometry for the investigation of radical cation chain reactions in solution: detection of transient radical cations. Anal Bioanal Chem 377: 1108–1114, 2003.[CrossRef][Web of Science][Medline]
  45. Momose I, Umezawa Y, Hirosawa S, Iijima M, Iinuma H, Ikeda D. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome. Biosci Biotechnol Biochem 69: 1733–1742, 2005.[CrossRef][Medline]
  46. Moore B. Bifunctional and moonlighting enzymes: lighting the way to regulatory control. Trends Plant Sci 9: 221–228, 2004.[CrossRef][Web of Science][Medline]
  47. Nakos G, Pneumatikos J, Tsangaris I, Tellis C, Lekka M. Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med 155: 945–951, 1997.[Abstract]
  48. Orlowski M, Cardozo C, Hidalgo MC, Michaud C. Regulation of the peptidylglutamyl-peptide hydrolyzing activity of the pituitary multicatalytic proteinase complex. Biochemistry 30: 5999–6005, 1991.[CrossRef][Medline]
  49. Orlowski M, Cardozo C, Michaud C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32: 1563–1572, 1993.[CrossRef][Medline]
  50. Peters JM, Franke WW, Kleinschmidt JA. Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. J Biol Chem 269: 7709–7718, 1994.[Abstract/Free Full Text]
  51. Ranford JC, Coates AR, Henderson B. Chaperonins are cell-signalling proteins: the unfolding biology of molecular chaperones. Expert Rev Mol Med 2000: 1–17, 2000.[Medline]
  52. Ranford JC, Henderson B. Chaperonins in disease: mechanisms, models, and treatments. Mol Pathol 55: 209–213, 2002.[Abstract/Free Full Text]
  53. Realini C, Dubiel W, Pratt G, Ferrell K, Rechsteiner M. Molecular cloning and expression of a gamma-interferon-inducible activator of the multicatalytic protease. J Biol Chem 269: 20727–20732, 1994.[Abstract/Free Full Text]
  54. Rivett AJ, Bose S, Pemberton AJ, Brooks P, Onion D, Shirley D, Stratford FL, Forti K. Assays of proteasome activity in relation to aging. Exp Gerontol 37: 1217–1222, 2002.[CrossRef][Web of Science][Medline]
  55. Sawada H, Sakai N, Abe Y, Tanaka E, Takahashi Y, Fujino J, Kodama E, Takizawa S, Yokosawa H. Extracellular ubiquitination and proteasome-mediated degradation of the ascidian sperm receptor. Proc Natl Acad Sci USA 99: 1223–1228, 2002.[Abstract/Free Full Text]
  56. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268: 579–582, 1995.[Abstract/Free Full Text]
  57. Shears SB. How versatile are inositol phosphate kinases? Biochem J 377: 265–280, 2004.[CrossRef][Web of Science][Medline]
  58. Sreedharan SK, Verma C, Caves LS, Brocklehurst SM, Gharbia SE, Shah HN, Brocklehurst K. Demonstration that 1-trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) is one of the most effective low Mr inhibitors of trypsin-catalysed hydrolysis. Characterization by kinetic analysis and by energy minimization and molecular dynamics simulation of the E-64-beta-trypsin complex. Biochem J 316: 777–786, 1996.[Web of Science][Medline]
  59. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 35: 3899–3908, 1996.[CrossRef][Medline]
  60. Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP, Meunier L. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol 152: 948–953, 2005.[CrossRef][Web of Science][Medline]
  61. Vaithilingam IS, McDonald W, Malott DW, Del Maestro RF. An extracellular proteasome-like structure from C6 astrocytoma cells with serine collagenase IV activity and metallo-dependent activity on alpha-casein and beta-insulin. J Biol Chem 270: 4588–4593, 1995.[Abstract/Free Full Text]
  62. Van Eldik LJ, Watterson DM. Reproducible production of antiserum against vertebrate calmodulin and determination of the immunoreactive site. J Biol Chem 256: 4205–4210, 1981.[Abstract/Free Full Text]
  63. Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 269: 29860–29866, 1994.[Abstract/Free Full Text]
  64. Walters DV. Lung lining liquid–the hidden depths. The 5th Nils W. Svenningsen memorial lecture. Biol Neonate 81, Suppl 1: 2–5, 2002.[CrossRef][Web of Science][Medline]
  65. Ware LB, Golden JA, Finkbeiner WE, Matthay MA. Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation. Am J Respir Crit Care Med 159: 980–988, 1999.[Abstract/Free Full Text]
  66. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J Neurochem 35: 1172–1182, 1980.[Web of Science][Medline]
  67. Wilkinson KD, Audhya TK. Stimulation of ATP-dependent proteolysis requires ubiquitin with the COOH-terminal sequence Arg-Gly-Gly. J Biol Chem 256: 9235–9241, 1981.[Abstract/Free Full Text]
  68. Williams MC. Endocytosis in alveolar type II cells: effect of charge and size of tracers. Proc Natl Acad Sci USA 81: 6054–6058, 1984.[Abstract/Free Full Text]
  69. Zoeger A, Blau M, Egerer K, Feist E, Dahlmann B. Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells. Clin Chem 52: 2079–2086, 2006.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. U. Sixt, M. Adamzik, D. Spyrka, B. Saul, J. Hakenbeck, J. Wohlschlaeger, U. Costabel, A. Kloss, J. Giesebrecht, B. Dahlmann, et al.
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome
Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
W. Huang, S. Y. Eum, I. E Andras, B. Hennig, and M. Toborek
PPAR{alpha} and PPAR{gamma} attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities
FASEB J, May 1, 2009; 23(5): 1596 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
G. A. Cornwall
New insights into epididymal biology and function
Hum. Reprod. Update, March 1, 2009; 15(2): 213 - 227.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/5/L1280    most recent
00140.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sixt, S. U.
Right arrow Articles by Peters, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sixt, S. U.
Right arrow Articles by Peters, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.